Teva Pharmaceutical: Investment Opportunity During Fed Rate Hike

Summary

• The Zantac lawsuit will have minimal impact on Teva Pharmaceutical's financial position.
• At the end of August 2022, the company received approval in Europe for Ranivisio, which is a biosimilar of Lucentis, which is a medicine used to treat patients with certain.
• Teva Pharmaceutical continues to publish new data on the efficacy and safety of key medicines, thereby increasing interest from doctors and patients.
• Most of Teva Pharmaceutical's senior notes have a fixed coupon and are thus less affected by the Fed's interest rate hike.

JHVEPhoto

Teva Pharmaceutical's (NYSE:TEVA) management continues to expand its product portfolio, gaining approval for Roche Holding's (OTCQX:RHHBY) (OTCQX:RHHBF) Lucentis biosimilar in Europe and expanding the database of efficacy and safety of the company's key brand drugs, driving

Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

This article may not take into account all the risks and catalysts for the stocks described in it. Any part of this analytical article is provided for informational purposes only, does not constitute an individual investment recommendation, investment idea, advice, offer to buy or sell securities, or other financial instruments. The completeness and accuracy of the information in the analytical article are not guaranteed. If any fundamental criteria or events change in the future, I do not assume any obligation to update this article.